Women with a BRCA 1 or 2 mutation carriers have an increased risk of developing breast cancer and ovarian cancer. However, the incidence of breast after developing ovarian cancer is unknown.
A 2022 multi-institutional retrospective study evaluated patients with a BRCA-associated ovarian cancer who were diagnosed between 1996 and 2016; the patients were followed for an average of 80 months. The results indicated that 184 patients with BRCA-associated ovarian cancer were identified and 18 (10%) patients were later diagnosed with breast cancer with a median follow-up of 48 months. The majority of breast cancers was diagnosed 3 years following an ovarian cancer diagnosis. In summary, ten percent of women developed breast cancer after first being diagnosed with breast cancer.
The incidence of breast cancer following ovarian cancer in BRCA mutation carriers increases over time, and thus, surveillance is recommended, especially considering these patients demonstrate enhanced ovarian cancer survival rates.
About Women’s Cancer Research Foundation
The Women’s Cancer Research Foundation (WCRF) is one of the most active research organizations in the nation. We are dedicated to studying and evaluating novel treatments for women afflicted with breast, ovarian, endometrial, and cervical cancers. The WCRF persistently endeavors to make a difference in women’s lives by offering them hope, strength, and progress.
Laguna Beach, CA 92651
PH: (949) 642-5165
Follow Us On Social Media:
留言